What is FluGen?
FluGen Inc. is a biotechnology firm dedicated to creating a more effective influenza vaccine through its innovative M2SR Vaccine Platform. The company's lead candidate, an intranasal M2SR vaccine, is engineered to elicit a broad immune response, offering protection against both seasonal and drifted influenza strains. FluGen specifically targets vulnerable populations, including the elderly and young, who face the highest risks from influenza and other respiratory illnesses. Beyond influenza, the company is investigating the M2SR platform's potential for combating COVID-19 and other respiratory pathogens, positioning itself at the forefront of infectious disease prevention.
How much funding has FluGen raised?
FluGen has raised a total of $20.4M across 5 funding rounds:
Debt
$3.2M
Other Financing Round
$9.4M
Series A
$2M
Debt
$5.5M
Debt
$234K
Debt (2014): $3.2M, investors not publicly disclosed
Other Financing Round (2015): $9.4M led by Knox Payments, Wisconsin Alumni Research Foundation, Venture Investors, and State of Wisconsin - Investment Board
Series A (2017): $2M supported by Knox Payments, Wisconsin Alumni Research Foundation, Venture Investors, and State of Wisconsin - Investment Board
Debt (2017): $5.5M, investors not publicly disclosed
Debt (2021): $234K backed by PPP
Key Investors in FluGen
Knox Payments
Associated with the University of Virginia, this entity likely supports academic and research-driven ventures, contributing to the development of innovative health solutions.
Wisconsin Alumni Research Foundation
WARF manages intellectual property from UW-Madison research, focusing on patenting and licensing discoveries to advance scientific innovation and support university research initiatives.
Venture Investors
Venture Investors Health Fund specializes in transformative healthcare innovations, investing in early-stage companies with the potential to significantly improve patient outcomes and advance medical science.
What's next for FluGen?
With substantial enterprise-level funding and a recent strategic investment, FluGen is poised for accelerated growth and the advancement of its M2SR vaccine platform. The company's focus on addressing unmet needs in flu prevention, coupled with its exploration of applications for COVID-19 and other respiratory diseases, indicates a strategic expansion into broader infectious disease markets. This capital infusion is expected to fuel further research and development, clinical trials, and potential commercialization efforts, solidifying FluGen's position as a key player in the vaccine development landscape.
See full FluGen company page
